Research Peptides in New Zealand: Import, GST and CoA Guide

A CoA is a test report for one specific manufactured batch, not a blanket claim about a product line. A usable report names the batch or lot number, the date of analysis, the laboratory that ran it, and the methods used. If the report cannot be tied to the vial in front of you by lot number, it tells you nothing about that vial.

Every Regena batch is externally tested before release: purity by HPLC (typically reported above 99%), identity confirmed by mass spectrometry, and residual water content measured — moisture matters because a lyophilised powder that has absorbed water degrades faster in storage. The report for the batch shipped ships with the order.

Regena supplies exclusively lyophilised peptides as reference standards for in vitro research. Nothing is reconstituted, and nothing is prepared for human or veterinary use.

The three numbers on a CoA answer three different questions. HPLC separates the sample and reports how much of it is the intended peptide versus related impurities — that is the purity percentage. Mass spectrometry measures molecular mass and confirms the peptide is the sequence it claims to be; high purity of the wrong molecule is still the wrong molecule.

Karl Fischer titration or an equivalent method measures residual moisture. Two vials with the same stated HPLC purity can behave differently in storage if one carries significantly more water. Reading all three together is what makes a report meaningful rather than a marketing figure.

New Zealand sits outside the EU, so an inbound shipment is a formal import rather than an intra-EU movement. Orders leave the Costa del Sol warehouse Monday to Friday via DHL Express or UPS Worldwide, with transit to Auckland, Wellington and Christchurch typically 5–14 days and tracking from dispatch to doorstep.

NZ Customs applies GST to imported goods above the current de minimis threshold, and duties can apply depending on classification. The courier handles express clearance and invoices any GST or duty directly to the recipient before delivery, so nothing is prepaid at checkout. Because thresholds and classifications change, confirm current rules with NZ Customs (customs.govt.nz) for your own shipment rather than relying on a supplier page.

Research chemicals imported for laboratory use are regulated differently from medicines. Medsafe governs medicines supplied for human use in New Zealand; reference standards for in vitro work are not supplied for that purpose and must not be used that way.

Temperature-sensitive peptides — BPC-157, GLP2, GLP3, GLP1 among them — ship in insulated packaging. Lyophilised powder is comparatively robust in transit: the freeze-dried state is what allows a 5–14 day journey to New Zealand without meaningful loss, which is why nothing is shipped reconstituted.

On arrival, check the vial seal and that the powder is intact rather than melted into a film, match the lot number against the CoA, and move the vials to cold storage. Humidity is the practical risk in coastal Auckland and Wellington: let a cold vial reach room temperature before opening so condensation does not form inside it.

New Zealand's seasons run opposite to the dispatch origin, which changes the practical risk profile across the year. A parcel leaving a European winter in January arrives into a New Zealand summer, so the warm end of the journey is at the destination rather than the origin — the reverse of what northern-hemisphere shipping guidance assumes. Insulated packing is used year-round for that reason rather than seasonally.

Freight to the South Island adds a domestic leg after international clearance. Christchurch, Dunedin, Queenstown and Invercargill are served by the courier's domestic network once the shipment clears in Auckland, and rural delivery addresses outside the main urban zones commonly add a further working day. Where an address is rural or a farm number, giving the courier a daytime contact number materially reduces failed-delivery cycles, which are the main cause of a vial sitting in a depot.

Distance makes verification more important, not less: a New Zealand buyer cannot inspect a warehouse, so the paper trail has to carry the weight. Ask for the certificate of analysis for the specific lot in stock before ordering, not a sample report from an older batch. Check that the report names an identifiable third-party laboratory and that the analysis date is close to the manufacturing date.

Where a report comes from an independent analytical lab, the report key can normally be verified on that laboratory's own site rather than taken from the supplier — Janoshik Analytical, for instance, publishes a verification page for its report keys. Verifying a key directly with the laboratory removes the supplier from the chain of trust entirely, which is the point of third-party testing.

It is also reasonable to ask why reports come from more than one laboratory. Batches manufactured at different facilities are tested where they are produced, so a supplier with multiple production sources will legitimately show reports from several labs; what matters is that each report is independent, current and traceable to the lot number on the vial.

Purchasing through a New Zealand university or Crown Research Institute normally requires more than a certificate of analysis. The standard document set is the COA for the lot in stock, a safety data sheet, a certificate of origin for the customs entry, and a written statement that the material is supplied as a reference standard for in vitro use. Requesting all four before raising a purchase order avoids the most common delay, which is a shipment held while paperwork is chased after dispatch rather than before it.

The research base these documents travel into is small but unusually concentrated: the University of Auckland and its Auckland Bioengineering Institute, the Malaghan Institute of Medical Research in Wellington, the University of Otago in Dunedin and Christchurch, and the Crown Research Institutes including AgResearch and ESR. Because the sector is compact, a single non-conforming document set tends to be remembered, which is why the paperwork discipline matters more here than in a larger market.

For a private laboratory or an independent researcher the same set is worth requesting anyway. The certificate of origin and the research-use declaration are what a courier's broker uses to classify the entry, and a correctly classified entry is the difference between a routine GST invoice and a shipment referred for inspection.

New Zealand splits oversight in a way that catches people out. Medsafe regulates medicines supplied for human use — that framework does not apply to a reference standard supplied for in vitro work, because such material is not supplied, labelled or intended for human use. The Environmental Protection Authority separately administers the Hazardous Substances and New Organisms regime, which governs how substances are classified and handled once they are in the country.

The practical consequence is that the correct question at the border is not "is this approved?" but "is this correctly declared and correctly classified?". A research-use declaration that matches the invoice description and the COA answers both. Where an institution has its own hazardous-substances register, adding the lot number and the water-content figure from the certificate at the point of receipt keeps the internal record consistent with the supplier record.

Nothing on this catalogue is authorised by Medsafe or any other regulator for human or veterinary use, and it must not be used that way.

A recurring question from New Zealand buyers, and a fair one: if a supplier is genuinely independent, why do certificates come from more than one laboratory? The answer is manufacturing rather than marketing. Batches are produced at different facilities, and each batch is tested where it is produced, so a supplier drawing on multiple production sources will legitimately hold reports from several analytical labs.

What should stay constant is the standard of the report, not its letterhead. Each one should be independent of the supplier, dated close to the manufacturing date, tied to the lot number stamped on the vial cap, and verifiable directly with the issuing laboratory rather than only as a PDF from the seller. Janoshik Analytical, whose reports appear most often in this market, publishes a verification page at janoshik.com/verify where a report key returns the report as the laboratory issued it.

Distance is the reason to be strict about this. A buyer in Dunedin cannot inspect a facility, so the verification chain has to do the work an inspection would do in person.

Pricing is quoted in euros and settled in euros, so the landed cost from New Zealand depends on the NZD/EUR rate on the day the payment clears rather than on a fixed NZ price list. Card payments convert at the card issuer's rate; a bank transfer converts at the bank's. The published catalogue price is the same for a Wellington laboratory as for a Madrid one — the difference is freight and the GST that NZ Customs assesses on arrival, both of which are billed separately and never bundled into the vial price.

Practical lead time from order to bench, counted end to end: same-day dispatch when the order is confirmed before 14:00 CET Monday to Friday, 5–14 days in transit to Auckland, one clearance step where GST is invoiced by the courier, and for South Island addresses one further domestic leg. Ordering on a Thursday afternoon European time usually means dispatch the same day; ordering on a Friday evening means Monday. Nothing about the distance changes what is shipped — lyophilised vials, one CoA per lot, insulated packing year-round.

Multi-vial kits matter more from New Zealand than from inside Europe, because freight and clearance are charged per shipment rather than per vial. Consolidating a quarter's requirement into one order is the single largest saving available on a New Zealand purchase, and it also reduces the number of customs entries a research group has to document internally.